Votrient patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7105530 NOVARTIS Pyrimidineamines as angiogenesis modulators
Oct, 2023

(24 days from now)

Votrient is owned by Novartis.

Votrient contains Pazopanib Hydrochloride.

Votrient has a total of 1 drug patent out of which 0 drug patents have expired.

Votrient was authorised for market use on 19 October, 2009.

Votrient is available in tablet;oral dosage forms.

The generics of Votrient are possible to be released after 19 October, 2023.

Drugs and Companies using PAZOPANIB HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2009

Treatment: NA


More Information on Dosage

VOTRIENT family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic